Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.

Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Baricitinib was effective in treating both early and late onset alopecia areata.

Baricitinib works better than methotrexate for severe alopecia areata.

Both azathioprine and betamethasone treatments effectively regrow hair in alopecia areata, but azathioprine may be safer.

Baricitinib significantly regrows hair in severe alopecia areata patients.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Mesalazine may help treat extensive alopecia areata effectively.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

SADBE treatment led to complete hair regrowth in mice with alopecia areata by altering immune cell movement.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.

Tofacitinib treatment is used for teenagers with alopecia areata.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.

Baricitinib improved hair loss and arthritis in a lupus patient.

Oral betamethasone mini-pulses effectively treat moderate to severe alopecia areata with manageable side effects.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Etanercept effectively treated a severe skin condition when other treatments failed.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.